CORONAVIRUS: DIAGNÓSTICO Y TERAPIA EN HUMANOS

VolverVolver

Resultados 350 resultados LastUpdate Última actualización 23/09/2021 [01:27:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 90 días/Published applications in the last 90 days



Página1 de 14 nextPage   por página


A device, computer program and method

NºPublicación: GB2593182A 22/09/2021

Solicitante:

SONY CORP [JP]
SONY EUROPE BV [GB]

EP_3883267_A2

Resumen de: GB2593182A

A method of distributing sound in a sporting venue, comprising: determining an event based on a position of at least one player and/or sporting projectile within the sporting venue. It involves selecting a sound effect based on the determined event; and sending the sound effect to at least one speaker located in the sporting venue. Preferably the projectile is a ball or a puck. Preferably the sound effect is one or more audio clips played together. Preferably, the sound volume is controlled based upon the event. In an aspect of the invention where the event is indicated rather than determined, the indication may be a scoring action or a video review. The current invention seeks to solve the issue of lack of crowd noise in sports matches due to empty stadiums as a result of Covid-19 or punishment by a sporting regulator.

traducir

DUAL DETECTION KIT FOR 2019 NOVEL CORONA VIRUS

NºPublicación: EP3882364A1 22/09/2021

Solicitante:

DAAN GENE CO LTD [CN]

WO_2021155638_A1

Resumen de: EP3882364A1

The present invention provides a novel coronavirus duplex detection kit. Specifically, the present invention discloses a kit and method for multiplex detection of novel coronavirus 2019-nCoV nucleic acid, which can simultaneously detect two nucleic acid targets of the novel coronavirus 2019-nCoV and possess extremely high sensitivity and specificity, and significantly improve the accuracy of virus identification.

traducir

FAMOTIDINE AND FAMOTIDINE ANALOGS FOR CORONA VIRUS TREATMENT

NºPublicación: WO2021183259A1 16/09/2021

Solicitante:

NANOPHARMACEUTICS INC [US]

Resumen de: WO2021183259A1

In silico screening of currently approved drugs against coronavirus SARS-CoV-2, PLpro (papain-like protease) resulted in the identification of famotidine and related analogs as potential antiviral candidates. PLpro (papain-like protease), a coronaviral protease, is essential for coronaviral replication. Famotidine, a histamine H2 antagonist, and a series of analogs repeatedly docked in the Cysl 12/His273/Asp287 catalytic triad pocket scored among the highest of the FDA-approved and over-the-counter compounds tested. Currently available as oral and IV products, famotidine appears in preliminary in silico screens to be useful to block PLpro activity and may be a potential treatment in patients who have contracted COVID-19 disease (caused by 2019-nCoV / SARS-CoV-2 infection). Famotidine has a very attractive profile with proven safety, drug interaction, and therapeutic window profiles.

traducir

ANTI-CORONAVIRUS ANTIBODIES AND METHODS OF USE

NºPublicación: WO2021183195A1 16/09/2021

Solicitante:

1 ABCELLERA BIOLOGICS INC [CA]
2 THE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES [US]

WO_2021183359_A1

Resumen de: WO2021183195A1

Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.

traducir

ALDEHYDE FUNCTIONAL MONOTERPENOIDS FOR THE TREATMENT OF CORONAVIRUS INFECTION

NºPublicación: US2021283162A1 16/09/2021

Solicitante:

COE WILLIAM B [US]

US_10993958_B1

Resumen de: US2021283162A1

Compositions comprising aldehyde functional monoterpenoids in combination with 3,3′,4′,7-tetrahydroxyflavone, zinc, and a 5-beta-D-Ribofuranosylpicolineamide adenine-dinucleotide molecule are provided for treating viral infections, e.g., coronavirus infections such as COVID-19.

traducir

METHODS FOR TREATING SARS COV-2 INFECTIONS

NºPublicación: US2021283150A1 16/09/2021

Solicitante:

GILEAD SCIENCES INC [US]

Resumen de: US2021283150A1

Provided are methods for treating 2019-nCoV virus (SARS-CoV-2) infections by administering nucleosides and prodrugs thereof, of Formula I:wherein the 1′ position of the nucleoside sugar is substituted.

traducir

METHOD FOR TREATMENT OF COVID-19-ASSOCIATED CONDITIONS

NºPublicación: US2021283152A1 16/09/2021

Solicitante:

RIGEL PHARMACEUTICALS INC [US]

Resumen de: US2021283152A1

Provided herein are a variety of methods that involve administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having or suspected of having a COVID-19 infection. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop acute respiratory distress syndrome, acute kidney injury, and/or thrombosis. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop symptoms associated with a cytokine response. Aspects of the methods may further include identifying a patient with kidney malfunction, e.g., acute kidney injury, and/or thrombosis.

traducir

COMPOSITIONS AND METHODS FOR DETECTING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2), INFLUENZA A AND INFLUENZA B

NºPublicación: US2021285061A1 16/09/2021

Solicitante:

ROCHE MOLECULAR SYSTEMS INC [US]

WO_2021180631_A1

Resumen de: US2021285061A1

Methods for the rapid detection of the presence or absence of SARS-CoV-2, influenza A and influenza B in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers and probes targeting SARS-CoV-2, influenza A, and influenza B and kits are provided that are designed for the detection of SARS-CoV-2, influenza A and influenza B.

traducir

COMPOSITIONS OF IL-6/IL-6R ANTIBODIES AND METHODS OF USE THEREOF

NºPublicación: US2021284743A1 16/09/2021

Solicitante:

TIZIANA LIFE SCIENCES PLC [GB]

WO_2021180821_A2

Resumen de: US2021284743A1

The present disclosure provides compositions and methods for the treatment of coronavirus infections, such as SAR-CoV, SARS-CoV-2, and MERS-CoV. The compositions include antibodies targeting the IL-6 receptor complex, antibodies targeting CD3, dactinomycin, and combinations thereof. The methods of treatment include administration of antibodies and combination therapies to reduce or eliminate symptoms associated with coronavirus infection or pulmonary inflammatory disease.

traducir

APPLICATION OF NANOPARTICLES TO TREAT INFECTIONS IN THE RESPIRATORY TRACT

NºPublicación: US2021283415A1 16/09/2021

Solicitante:

KASSAB GHASSAN S [US]
DABIRI ALI [US]

Resumen de: US2021283415A1

A method of using nanoparticle (NP) spray to treat an infection in the respiratory system and far infrared radiation (FIR) to treat inflammation. The method uses a spray probe inserted into the airway of a patient to apply mSiO2 and FIR to a target site in the upper respiratory tract. FIR applied may be in the 3-10 μm range. The mSiO2 spray kills any organisms, including COVID-19 and FIR reduces inflammation resulting from infection. The treatment may be applied to intubated or spontaneously breathing patients and via the oral or nasal passages.

traducir

APPLICATION OF UV/FIR TO TREAT INFECTIONS IN THE RESPIRATORY TRACT

NºPublicación: US2021283356A1 16/09/2021

Solicitante:

KASSAB GHASSAN S [US]
DABIRI ALI [US]

Resumen de: US2021283356A1

A method of using ultraviolet (UV) radiation to treat an infection in the respiratory system and far infrared radiation (FIR) to treat inflammation. The method uses a light probe inserted into the airway of a patient to apply UV radiation and FIR to a target site in the upper respiratory tract. The UV radiation applied may be broad-spectrum UV radiation or UVC radiation in the 222 nm range. FIR applied may be in the 3-10 μm range. The UV radiation kills any organisms, including COVID-19 and FIR reduces inflammation resulting from infection and subsequent UV treatment. The treatment may be applied to intubated or spontaneously breathing patients and via the oral or nasal passages.

traducir

ADENOVIRUS-VECTORED VACCINE FOR PREVENTING SARS-COV-2 INFECTION

NºPublicación: US2021283244A1 16/09/2021

Solicitante:

GUANGZHOU N BIOMED LTD [CN]

WO_2021000968_A2

Resumen de: US2021283244A1

The present disclosure discloses an adenovirus vectored vaccine for preventing SARS-CoV-2 infection, which comprises a nucleotide sequence as shown by SEQ ID NO: 1. According to some embodiments of the present disclosure, the vaccine comprises an S protein-coding nucleotide sequence which is easily expressed in human cells, and can produce more S proteins. The vaccine of the present disclosure is expected to be used as a recombinant viral vaccine for preventing SARS-CoV-2 infection. Some embodiments of the present disclosure have better safety.

traducir

RESPIRATORY THERAPEUTIC ELECTRIC HEAT SOURCE FACE MASK

NºPublicación: US2021282964A1 16/09/2021

Solicitante:

SABIN ROBERT [US]

Resumen de: US2021282964A1

An improved face mask with a temperature monitored resilient, flexible face barrier to limit the face, eyes, lips, and oral tissues of the mouth of the user from direct exposure to heated air from the mask above threshold temperatures. The improved face mask and heat source conditions air drawn into the face mask before it is actually breathed and thereby supply heated or elevated higher temperature at a therapeutic air pressure to persons in need thereof, particularly to maintain a wearer's upper respiratory system at a further elevated high temperature, capable of inactivating viruses, such as the Coronavirus 2 (SARS CoV-2 virus), killing bacteria, (TB) fungi, biofilms, tumor cells, pre-malignant cancer cells, dysplasia cells and other pathogens, and to promote an immune-stimulatory response and to prevent or inactivate a virus in the respiratory system of the wearer of the heated face mask, in both ambulatory and hospitalization settings.

traducir

Anti COVID-19 Therapies targeting nucleocapsid and spike proteins

NºPublicación: US2021283245A1 16/09/2021

Solicitante:

IMMUNITYBIO INC [US]
GLOBEIMMUNE INC [US]

US_2021284716_A1

Resumen de: US2021283245A1

Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a nucleocapsid protein of coronavirus 2 (CoV2); and/or wherein the recombinant entity encodes a spike protein of CoV2.

traducir

LICHENASE-COVID-19 BASED VACCINE

NºPublicación: US2021283243A1 16/09/2021

Solicitante:

IBIO INC [US]

Resumen de: US2021283243A1

The present invention includes an immunogenic protein, nucleic acid, plant and immunization comprising a fusion protein that has at least 90% amino acid identity to an amino acid sequence of a modified thermostable lichenase (LicKM) polypeptide as set forth in SEQ ID NO:9, wherein the LicKM polypeptide comprises an N-terminus, a C-terminus, and an inner loop region, and wherein a Receptor Binding Domain (RBD) or a Receptor Binding Motif (RBM) of a coronavirus spike protein is positioned at, at least one of, the N-terminus, the C-terminus, or in a loop region of the LicKM polypeptide.

traducir

Systems and Methods for Treating Patients Infected with SARS-COV-2

NºPublicación: US2021283201A1 16/09/2021

Solicitante:

HDL THERAPEUTICS INC [US]

WO_2021178582_A2

Resumen de: US2021283201A1

The present specification describes methods and systems for treating a patient having a SARS-CoV-2 virus load greater than a predefined threshold. A patient is assessed to determine if the patient has the SARS-CoV-2 virus load greater than the predefined threshold. If the patient has the SARS-CoV-2 virus load greater than the predefined threshold, a volume of plasma is removed from the patient. In a plasma delipidation system, the volume of plasma is mixed with an extraction solvent to delipidate at least some of the SARS-CoV-2 viruses in the patient's SARS-CoV-2 virus load, thereby causing one or more modifications to the SARS-CoV-2 viruses. The extraction solvent is removed from the plasma and the plasma is administered with the at least some of the delipidated SARS-CoV-2 viruses to the patient.

traducir

ANTI COVID-19 THERAPIES USING CD40 LIGAND FUSION PROTEIN

NºPublicación: US2021284713A1 16/09/2021

Solicitante:

IMMUNITYBIO INC [US]

Resumen de: US2021284713A1

Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a extracellular portion of CD40 ligand (CD40L) coupled by a flexible linker to a coronavirus 2 (CoV2) spike protein and/or a CoV2 nucleocapsid protein.

traducir

THE CHEMICAL COMPOSITION FOR IMPREGNATION VIA SPRAYING ON DISPOSABLE SUGICAL MASKS, SLEEVES GOWNS MADE FROM HYDROPHILIC AND HYDROPHOBIC MATERIALS FOR THE INACTIVATION OF BACTERIA AND VIRUSES SUCH AS CORONAVIRUS, SARS, MERS, INFLUENZA A AND INFLUENZA B VIRUSES

NºPublicación: WO2021183041A1 16/09/2021

Solicitante:

KIT YEW CHENG [SG]

Resumen de: WO2021183041A1

This invention relates to the Chemical Composition for impregnation via spraying on disposal surgical masks and sleeved gowns made from hydrophilic and hydrophobic materials to inactivate bacteria and viruses, comprising of colloidal silver nanoparticles, Isopropanol Alcohol/ Ethanol Alcohol Chlorhexidine/Quaternary Ammonium Compound, Peppermint/ Spearmint Essential oils and water.

traducir

METHOD FOR TREATMENT OF COVID-19-ASSOCIATED CONDITIONS

NºPublicación: WO2021183790A1 16/09/2021

Solicitante:

RIGEL PHARMACEUTICALS INC [US]

Resumen de: WO2021183790A1

Provided herein are a variety of methods that involve administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having or suspected of having a COVID-19 infection. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop acute respiratory distress syndrome, acute kidney injury, and/or thrombosis. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop symptoms associated with a cytokine response. Aspects of the methods may further include identifying a patient with kidney malfunction, e.g., acute kidney injury, and/or thrombosis.

traducir

LICHENASE-COVID-19 BASED VACCINE

NºPublicación: WO2021183780A1 16/09/2021

Solicitante:

IBIO INC [US]

US_2021283243_A1

Resumen de: WO2021183780A1

The present invention includes an immunogenic protein, nucleic acid, plant and immunization comprising a fusion protein that has at least 90% amino acid identity to an amino acid sequence of a modified thermostable lichenase (LicKM) polypeptide as set forth in SEQ ID NO:9, wherein the LicKM polypeptide comprises an N-terminus, a C-terminus, and an inner loop region, and wherein a Receptor Binding Domain (RBD) or a Receptor Binding Motif (RBM) of a coronavirus spike protein is positioned at, at least one of, the N-terminus, the C-terminus, or in a loop region of the LicKM polypeptide.

traducir

TREATMENT OF COVID-19 AND METHODS THEREFOR

NºPublicación: WO2021183665A1 16/09/2021

Solicitante:

NANT HOLDINGS IP LLC [US]

Resumen de: WO2021183665A1

A vaccine composition to induce immunity against a coronavirus in a subject comprises a recombinant nucleic acid that encodes N-ETSD, a modified nucleocapsid protein that includes an endosomal targeting sequence, and/or that encodes S-Fusion, a modified spike protein that has improved surface expression. The vaccine may be formulated as a recombinant nucleic acid, recombinant yeast, and/or recombinant virus such as an adenovirus and can be administered via injection and/or mucosal delivery.

traducir

METHODS AND KITS FOR THE DETECTION OF SARS-COV-2

NºPublicación: WO2021183902A1 16/09/2021

Solicitante:

TRANSLATIONAL GENOMICS RES INST [US]

Resumen de: WO2021183902A1

Methods, kits, and oligonucleotides used in the detection of the coronavirus strain, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are disclosed. In some aspects, the oligonucleotides are primers or probes used in the described methods or kits. The oligonucleotide consists of 42 or less nucleotides and has a nucleotide sequence that consists essentially of, or is a variant of, the nucleotide sequence of: SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7. In some embodiments, the oligonucleotide is modified with an internal spacer or a detectable label. For example, the 5' terminus is labeled with a fluorophore and the 3' terminus is complexed to a quencher of fluorescence of said fluorophore. In some embodiments, the nucleotide sequence of the oligonucleotide further comprises a universal tail sequence.

traducir

APPLICATION OF HERBAL MEDICINE COMPOSITION IN PREPARATION OF MEDICINE FOR PREVENTING AND TREATING CORONAVIRUS COMPLICATED WITH LUNG INJURY

NºPublicación: WO2021179881A1 16/09/2021

Solicitante:

GUANGDONG LEIYUNSHANG PHARMACEUTICAL CO LTD [CN]

CN_113144010_A

Resumen de: WO2021179881A1

Disclosed is an application of an herbal medicine composition in the preparation of a medicine for preventing and treating novel coronavirus complicated with lung injury. In the invention, the intervention effect of the herbal medicine composition on the novel coronavirus (SARS-CoV-2) is screened, and a clinical experiment result shows that the herbal medicine composition has a good effect of inhibiting lung injury and lung fibrosis caused by the novel coronavirus (SARS-CoV-2). The herbal medicine composition may improve the levels of albumin, lymphocyte, lymphocyte percentage, neutrophil and CD8 cells and reduce the levels of C reactive protein and lactate dehydrogenase. The herbal medicine composition can assist treatment of the novel coronavirus complicated with lung injury, and the recovery rate may be improved. In addition, clinical experiment results show that the herbal medicine composition of the present invention has obvious effects in terms of respiratory function after the novel coronavirus (SARS-CoV-2) infection, relieving the fatigue of patients, and enhancing the exercise ability thereof.

traducir

DETECTION OF IMMUNE RESPONSE TO SARS-COV-2

NºPublicación: WO2021179418A1 16/09/2021

Solicitante:

UNIV TSINGHUA [CN]

Resumen de: WO2021179418A1

Use of two viral antigens in a preparation of kit used to detect antibody against SARS-Cov-2 in a subject, wherein the antigens comprise the followings: a first antigen comprises at least a part of a nucleocapsidphosphoprotein; and a second antigen comprises at least a part of a Spike protein.

traducir

POLYPEPTIDE, POLYPEPTIDE VACCINE AND APPLICATION THEREOF

Nº publicación: WO2021180233A1 16/09/2021

Solicitante:

ICARBONX ZHUHAI COMPANY LTD [CN]

WO_2021180232_A1

Resumen de: WO2021180233A1

Provided is a polypeptide, the amino acid sequences thereof being SEQ ID NOs: 1-154. By combining polypeptide chip technology, 40 polypeptides specifically related to coronavirus infections, particularly the SARS-CoV-2 virus infection, are screened out and obtained, the amino acid sequences thereof are represented by SEQ ID NOs: 1-40, and polypeptide vaccines, nucleic acid vaccines, recombinant protein vaccines, and so on can be prepared.

traducir

Página1 de 14 nextPage por página

punteroimgVolver